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Neuroendocrine control of the reproductive cascade
is mediated by GnRH, which in mammals is produced
by a subset of neurons scattered throughout the hy-
pothalamus and forebrain. Utilizing a cultured cell
model of GnRH neurons (GT1–7 cells), two regulatory
regions in the rat GnRH 5* flanking DNA were iden-
tified as essential for cell-type specificity: a 300-bp
enhancer and a 173-bp conserved proximal pro-
moter. Using transient transfections to compare ex-
pression in GT1–7 cells to a non-GnRH-expressing
cell type (NIH 3T3), we show that the GnRH enhancer
and the proximal promoter each play roles in confer-
ring this specificity. Deletion of footprint 2 (FP2; 226
to 276) from the promoter when coupled to the
GnRH enhancer diminishes reporter activity in GT1–7
cells more strongly than in NIH 3T3 cells. Further-
more, deletion of FP2 from the promoter when cou-
pled to the heterologous Rous sarcoma virus 5*-long
terminal repeat promoter abolishes the difference in
reporter activity between GT1–7 and NIH 3T3 cells,
suggesting that FP2 of the GnRH promoter is neces-
sary for cell-specific expression. In addition, FP2
alone is sufficient to confer cell-specific expression
and can interact with the GnRH enhancer to augment
reporter gene expression specifically in GT1–7 cells.
Finally, a 31-bp sequence from within FP2 (263 to
233) synergistically activates transcription when
coupled with the GnRH enhancer in GT1–7 cells but
not in NIH 3T3 cells. Thus, this 31-bp region contains
elements necessary for interaction between the
GnRH enhancer and promoter. We show that two of
five protein complexes that bind to the 263 to 233
region are GT1–7 cell specific, and both of them ap-
pear to be homeodomain proteins. The identification
of a cell-specific element in the GnRH proximal pro-
moter significantly advances our understanding of
the transcriptional basis for neuron-specific GnRH
gene expression. (Molecular Endocrinology 14: 1509–
1522, 2000)
INTRODUCTION
GnRH, an essential reproductive hormone expressed
in a restricted subset of neurons scattered throughout
the hypothalamus of mammals, is a decapeptide se-
creted in a pulsatile manner from axonal terminals at
the median eminence (1, 2). GnRH neurons have a
unique embryological origin, migrating from the olfac-
tory placode where they arise at embryonic day 11 in
the mouse (3). Currently, the only known unique iden-
tifier of GnRH neurons is GnRH itself. However, deter-
minants of cell identity must be involved in the devel-
opment and maintenance of GnRH gene expression.
These genes could either encode specific transcrip-
tional activators or a unique combination of more gen-
erally expressed transcription factors expressed only
in GnRH neurons.
An excellent model system for examination of GnRH
gene transcription is the GT1–7 cell line. The GT1–7
cell line was immortalized by targeting the oncogene,
SV40 T antigen, to GnRH neurons using the 59-flanking
region of the rat GnRH gene in transgenic mice. The
culturing of a hypothalamic tumor derived from such
mice facilitated the clonal isolation of the GT1–1,
GT1–3, and GT1–7 cell lines (4). These cell lines have
been invaluable in studying GnRH gene expression,
allowing a detailed analysis of the rat GnRH gene
regulatory region. A 300-bp enhancer (21863 to
21571) was identified by deletion analysis of a 3-kb
59-regulatory region of the rat GnRH gene (5). Addi-
tionally, a conserved 173-bp promoter was identified
by cross-species similarity (6). Fusion of the GnRH
0888-8809/00/$3.00/0
Molecular Endocrinology 14(9): 1509–1522




enhancer to the GnRH promoter in a reporter gene
plasmid recapitulates the activity seen with the 3-kb
59-flanking region in transient transfection assays (5)
and in transgenic mice (M. A. Lawson, S. B. Nelson,
and P. L. Mellon, unpublished).
Many transcription factors have been found to interact
with the rat GnRH regulatory regions including Oct-1,
GATA-4, SCIP/Tst-1, and Otx2 (Refs. 7–10a). All of these
proteins were identified utilizing the GT1–7 GnRH neu-
ronal model system, and colocalization with GnRH has
been confirmed in vivo by immunohistochemistry and/or
in situ hybridization. Oct-1, a POU-homeodomain tran-
scription factor, binds to two regions within the GnRH
enhancer and two regions within the GnRH promoter (7,
11). GATA-4 binds to one site in the GnRH enhancer, and
its expression colocalizes with GnRH neurons during
embryonic development (8, 9, 12). In vitro synthesized
SCIP binds to regions within the GnRH promoter and
colocalizes with GnRH expression during mouse embry-
onic development (10). Otx2, a homeoprotein required
for anterior head development (13–15) related to the
Orthodenticle gene in Drosophila, binds to a single site in
the promoter and colocalizes with GnRH in the embryo
during migration and in the adult hypothalamus (10a).
Although a few of the proteins that bind to the rat GnRH
enhancer and promoter have now been identified, none
of these proteins is restricted uniquely to the GnRH neu-
rons, supporting the hypothesis that a unique combina-
tion of proteins control GnRH-specific expression.
Interactions between the rat GnRH enhancer and pro-
moter are important for maintaining a high level of re-
porter gene transcription specifically in GT1–7 cells. The
enhancer activates transcription of the heterologous
Herpesvirus thymidine kinase promoter (TK) only 4 fold in
GT1–7 cells, yet when placed upstream of the GnRH
promoter, the enhancer activates transcription 55-fold
(5). Therefore, interactions must exist between the en-
hancer and promoter to cause this specific increase in
transcriptional activity in GT1–7 cells. We have devised a
transient transfection paradigm to compare reporter
gene expression between different cell lines. This ap-
proach has allowed us to determine that a 62-bp region
of the GnRH promoter (footprint 2; FP2) is necessary and
sufficient to confer neuronal specificity of GnRH gene
expression in vitro. Additionally, a 31-bp element from
within FP2 acts synergistically with the enhancer and
binds two GT1–7 cell-specific protein complexes, both
of which may be homeodomain proteins.
RESULTS
Individual Roles for the Enhancer and Promoter
in GT1–7 Cell-Specific Expression of the Rat
GnRH Gene
The rat GnRH regulatory region contains a 300-bp
neuron-specific enhancer (21863 to 21571) and a
conserved 173-bp promoter. To test the participation
of these two regions in conferring neuron-specific
transcription, each element was placed into a heter-
ologous context (Fig. 1). To accomplish this, chimeric
regulatory regions were constructed using the GnRH
enhancer and promoter and the enhancer and pro-
Fig. 1. The Rat GnRH Enhancer and Promoter Have Individual Roles in Cell Type-Specific Expression
Transient transfections were conducted in JEG-3, CV1, NIH 3T3, and GT1–7 cells (identified by hatched, black, white, and gray
bars, respectively). Diagrams at left depict luciferase reporter plasmids: the RSV enhancer fused to the RSV promoter (RSVe/
RSVp-luc), the GnRH enhancer (21863 to 21571) fused to the GnRH promoter (2173 to 1112) (rGnRHe/rGnRHp-luc), the GnRH
enhancer fused to the RSV promoter (rGnRHe/RSVp-luc), and the RSV enhancer fused to the GnRH promoter (RSVe/rGnRHp-
luc). The mean value for the RSVe/RSVp-luc divided by RSVe/RSVp-gal (internal control) is set to 1 for each cell type as shown.
Error bars represent SEM of at least three experiments conducted in duplicate. Asterisks designate statistical differences from
GT1–7 values of P 5 0.001. Note that the x-axis is shown as a log scale to accommodate the large differences in expression.
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moter elements of the Rous sarcoma virus (RSV) 59-
long terminal repeat (LTR). Specifically, the heterolo-
gous RSV enhancer was fused to the GnRH promoter
(RSVe/rGnRHp-luc), and the GnRH enhancer was
fused to the RSV promoter (rGnRHe/RSVp-luc). These
regulatory regions were engineered upstream of the
luciferase reporter gene in a reporter plasmid vector.
As controls, reporter genes containing the RSV en-
hancer on the RSV promoter (RSVe/RSVp-luc) or the
combination of the GnRH enhancer and promoter
(rGnRHe/rGnRHp-luc) were also prepared. These
plasmids were transfected into four different cell lines,
NIH 3T3 (mouse fibroblasts), GT1–7 (mouse GnRH
expressing neurons), JEG-3 (human placental), and
CV1 (monkey kidney fibroblasts). To control for differ-
ences in transfection efficiency and relative expression
level in various cell types, the RSV enhancer and the
RSV promoter fused to the Escherichia coli b-galac-
tosidase gene (RSVe/RSVp-gal) was used as an inter-
nal control in all transfections. The ratio of RSVe/
RSVp-luc values to RSVe/RSVp-gal values was set to
1 for each cell type. The relative expression levels of
the various reporter genes in the cell types indicated in
Fig. 1 are depicted on a log scale since the differences
are dramatic. There is a significantly higher level of
reporter gene expression in GT1–7 cells than in the
other three cell types with the rGnRHe/rGnRHp-luc,
rGnRHe/RSVp-luc, and RSVe/rGnRHp-luc regulatory
regions. These data show that the GnRH enhancer
and the GnRH promoter each play roles in determining
GT1–7 cell-specific expression and that the combina-
tion of the GnRH enhancer and promoter together
yields a synergistic degree of specificity.
FP2 Is Necessary for Cell-Specific Expression
Previously, seven protein-binding regions within the
rat GnRH promoter were identified by DNAse I protec-
tion assays (DNA footprinting) with GT1–7 nuclear ex-
tract (6, 16). Footprint 1 (FP1) contains the TATA box
and transcriptional start site. Deletion of footprint 2
(FP2, 226 to 276) results in a 20-fold loss of reporter
gene activity in GT1–7 cells. Footprint 3 (FP3, 279 to
285) does not bind proteins in electrophoretic mobility
shift assays (EMSA), but a complex does form on this
region with nuclear proteins from GT1–7 cells treated
with human chorionic gonadotropin (17). Footprint 4
(FP4, 289 to 2110) binds at least five protein com-
plexes in EMSA, one of which is Oct-1 (11). Footprint
5 (FP5, 2112 to 2127) binds one protein complex in
EMSA. Deletion of three footprints, 3, 4, and 5, results
in a 50% reduction in reporter gene activity (6). Dele-
tion of footprint 6 (FP6, 2129 to 2158) and footprint 7
(FP7, 2161 to 2173) also results in a 50% decrease in
reporter gene activity (6). Additionally, it has been
shown that Otx-2 binds to FP6 and a 4-bp mutation in
the binding site reduces activity to 20% of wild type
(10a). Thus, all of these regions contribute to activation
of transcription of the GnRH gene.
To identify the cell-specific element(s), 59 and inter-
nal deletions were created within the GnRH promoter
and transfected into GT1–7 cells, and the results were
compared with those from parallel transfections into
NIH 3T3 cells. Subsections of the promoter containing
various footprinted regions were placed downstream
of the GnRH enhancer (Fig. 2A), as previously de-
scribed by Eraly et al. (6), or the heterologous RSV
enhancer (Fig. 2B). Here, we have used vectors con-
taining the luciferase reporter gene instead of the
chloramphenicol transferase reporter gene. When the
59 and internally deleted promoter regions are placed
downstream of the GnRH enhancer, reporter expres-
sion in GT1–7 cells was consistently higher than in NIH
3T3 cells (Fig. 2A). This result demonstrates that the
GnRH enhancer can confer specificity in a heterolo-
gous context (5). The relative difference in reporter
gene expression between the two cell types can be
calculated by dividing the GT1–7 values by the NIH
3T3 values (Fig. 2A at right, relative activity). It is ap-
parent from these comparisons that a large decrease
in cell type specificity occurs when FP2 is individually
deleted and when FP2 through FP7 are deleted (note
the log scale). The role for FP2 in cell type specificity
is further substantiated by transient transfections with
the deletions placed downstream of the RSV enhancer
(Fig. 2B). Here again, there is a higher level of reporter
gene expression in GT1–7 cells compared with the
NIH 3T3 cells with the full-length 173-bp promoter
although the degree of difference is diminished due to
the lack of the GnRH enhancer. The individual deletion
of FP2 results in a loss of cell type specificity since
both the GT1–7 cells and the NIH 3T3 cells express the
reporter gene to the same degree. Additionally, when
FP2 was reinserted, cell specificity reappears. It re-
mains unclear why deletion of FP2 through FP7 does
not completely abolish the cell-specific expression,
but this result may indicate that there is some speci-
ficity inherent to the TATA box machinery.
FP2 (282 to 221) or 263/233 Can Interact with
the GnRH Enhancer to Augment Expression
To test for interactions of FP2 with the GnRH en-
hancer, FP2 (282 to 221) was inserted between the
GnRH enhancer and the heterologous RSV promoter
(rGnRHe/FP2/RSVp-luc). The insertion of FP2 into this
context results in a large increase in reporter gene
expression in GT1–7 cells in comparison to NIH 3T3
cells (Fig. 3A). To determine whether a smaller region
of FP2 can confer cell type specificity, transcriptional
analysis of a 4-fold multimerized 263 to 233 region
(43263/233) was conducted. The reporter plasmids
contained the GnRH enhancer fused to 43263/233
and the RSV promoter (rGnRHe/4X63/RSVp-luc).
When transfected into GT1–7 cells, rGnRHe/4X63/
RSVp-luc increased reporter gene expression com-
pared with the rGnrHe/RSVp-luc (Fig. 3A). This in-
crease was not as great as that seen with FP2, but it
does suggest that 43 263/233 synergizes with the
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GnRH enhancer. Thus, we can conclude that both FP2
and 43263/233 can act synergistically with the
GnRH enhancer to confer cell type specificity.
FP2, but Not 263/233, Is Sufficient to Confer
Neuron-Specific Expression
To determine whether the FP2 region can enhance
neuronal specificity in a completely heterologous con-
text, FP2 was inserted between the RSV enhancer and
the RSV promoter (RSVe/FP2/RSVp-luc). Here we see
a significant decrease in reporter gene expression in
both cell types (Fig. 3B) possibly due to the additional
62 bp inserted between the RSV enhancer and pro-
moter. Regardless of this overall decrease in expres-
sion, there is a higher level of reporter gene expression
in GT1–7 cells compared with NIH 3T3 cells. Addition-
ally, transfections into aT3–1 (a mouse pituitary gona-
dotrope cell line immortalized in the same manner as
GT1–7 cells) and IMR-32 (a human neuroblastoma cell
line), showed lower relative activity than expression in
NIH 3T3 cells (data not shown), indicating that NIH 3T3
cells provide the best comparison with GT1–7 cells.
Internal block mutations within FP2 in the context of
the RSV enhancer and GnRH promoter did not result in
a change in the relative difference between reporter
Fig. 2. Deletion of Footprint 2 Decreases the Ratio of GT1–7 to NIH 3T3 Activity When Coupled to the GnRH Enhancer and
Eliminates the Cell Type-Specific Difference When Coupled to the RSV Enhancer
Transient transfections were conducted in NIH 3T3 and GT1–7 cells (identified by white and gray bars, respectively). The mean
value for RSVe/RSVp-luc divided by RSVe/RSVp-gal is set to 1 for each cell type (bars shown in A but not in B). The activity ratios
are the values in GT1–7 cells divided by the values in the NIH 3T3 cells. A, The GnRH enhancer fused to the full-length GnRH
promoter or deletions of the GnRH promoter are shown at left. Values are depicted on a log scale. B, The RSV enhancer fused
to the full-length GnRH promoter or deletions of the GnRH promoter are shown at left. Asterisks identify significant differences
between the GT1–7 and NIH 3T3 values by paired t test, P 5 0.001. Error bars represents SEM of at least three experiments
conducted in duplicate.
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expression in GT1–7 vs. NIH 3T3 cells (data not
shown). Thus, specific sequences required for this
GT1–7 cell-specific expression could not be further
localized. To determine whether the smaller region of
FP2 is able to confer cell type specificity, transcrip-
tional analysis of the 4-fold multimerized 263 to 233
region was conducted. The reporter plasmids con-
tained the RSV enhancer fused to 43 263/233 and
the RSV promoter (RSVe/4X63/RSVp-luc). Reporter
gene expression levels were higher in NIH 3T3 cells
than in GT1–7 cells, demonstrating that the 43263/
233 is not able to act independently when placed in a
heterologous context. Thus, we have identified FP2 as
the smallest region (62 bp) of the GnRH promoter that
is sufficient to autonomously confer cell-specific ex-
pression of the GnRH gene.
Complexes Specific to GT1–7 Nuclear Extract
Bind the 263/233 Element
Interactions between the GnRH enhancer and GnRH
promoter are likely what confer the cell-specific ex-
pression of the GnRH gene based on our evidence
(Figs. 1–3) and evidence obtained in transgenic mice
(M. A. Lawson and P. L. Mellon, unpublished obser-
vations). Having demonstrated that both FP2 and the
263 to 233 promoter elements interact with the en-
hancer to specify reporter gene expression to GT1–7
cells, we next wanted to determine what proteins may
bind to this region to confer cell specificity. We chose
to analyze the 263 to 233 region because it contains
fewer potential protein binding sites, while still main-
taining the capability of interacting with the GnRH
Fig. 3. Footprint 2 Is Sufficient to Confer Cell Type Specificity
A, Footprint 2 synergizes with the GnRH enhancer to augment reporter gene expression exclusively in GT1–7 cells. B, FP2 in
a heterologous context is sufficient to increase cell type specificity but the multimerized 263/233 element is not. Transient
transfections were conducted in NIH 3T3 and GT1–7 cells (identified by white and gray bars, respectively). The mean value for
the RSVe/RSVp-luc divided by RSVe/RSVp-gal is set to 1 for each cell type (shown in B, but not in A). The activity ratios are the
values in GT1–7 cells divided by values in NIH 3T3 cells, shown at right. Diagrams at left depict luciferase reporter plasmids: A,
the GnRH enhancer fused to the GnRH promoter, the GnRH enhancer fused to the RSV promoter, FP2 inserted between the
GnRH enhancer and the RSV promoter, and 43263/233 inserted between the GnRH enhancer and the RSV promoter; B, the
RSV enhancer fused to the RSV promoter, FP2 inserted between the RSV enhancer and promoter, and 43263/233 inserted
between the RSV enhancer and promoter. Asterisks represent significant difference between values in GT1–7 and NIH 3T3 cells
by paired t test, P , 0.01. Error bars represent SEM of at least three experiments conducted in duplicate.
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Fig. 4. Oct-1 Binding within Footprint 2
EMSA was conducted with three different nuclear extracts; GT1–7 (GnRH expressing cell line), NIH 3T3 (mouse fibroblast cell
line), and aT3–1 (mouse pituitary gonadotrope cell line). Antibodies were added to the reactions, Oct-1 (antibody against Oct-1)
and normal rabbit IgG (nonspecific antibody). Arrow at bottom right indicates migration of free probe. A, Oct-1 forms complex
5 in GT1–7 and aT3–1 nuclear extracts but not in NIH 3T3 nuclear extract using the 263/233 probe. The specific complexes
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enhancer to confer cell specificity. Previously, we have
identified five GT1–7 nuclear protein complexes bind-
ing to 263/233, one of which is Oct-1 (complex 5)
(11). In these experiments, we used EMSA to compare
the protein complexes bound to the 263/233 element
in GT1–7 nuclear extract with NIH 3T3 nuclear extract
(Fig. 4A). Nuclear extract from aT3–1 cells was in-
cluded as a second cell type that does not express
GnRH. The low mobility complex formed with GT1–7
nuclear extract (complex 5) was previously identified
as Oct-1 by antibody supershift analysis (11). In EMSA
with NIH 3T3 nuclear extract, a complex comigrates
with the Oct-1 band from the GT1–7 cells, but addition
of an antibody against Oct-1 does not block binding of
the complex. The Oct-1 antibody blocks binding of
complex 5 in GT1–7 and aT3–1 nuclear extract. These
data suggest that either Oct-1 does not bind to FP2 in
NIH 3T3 cells or that another complex binding with
NIH 3T3 nuclear extract masks the binding of Oct-1.
Regardless, the major low mobility complex in NIH 3T3
extracts binding to 263/233 does not contain a sig-
nificant amount of Oct-1, which may account for the
lower transcriptional activity observed in Figs. 1 and 2.
To prove that functional Oct-1 is present in NIH 3T3
cells, we show that Oct-1 from NIH 3T3 and GT1–7
nuclear extracts binds appropriately to an octamer
consensus sequence (Fig. 4B). Oct-1 binding to 263/
233 is not unique to GT1–7 nuclear extract since
nuclear extract from aT3–1 cells forms the Oct-1 com-
plex (Fig. 4A). Additionally, two complexes with a high
mobility (complexes 1 and 2) are present in EMSA with
GT1–7 nuclear extract but not with NIH 3T3. In aT3–1
nuclear extract, complex 1, but not complex 2, is
present by EMSA. These differences in protein com-
plexes binding to FP2 could be responsible for the cell
type-specific interactions between the GnRH en-
hancer and promoter.
To determine whether complex 1 and 2 binding to
263/233 are specific across various cell types, a
panel of nuclear extracts was used in EMSA with 263/
233 as a probe (Fig. 5). The nuclear extracts were from
the following cell lines: GT1–7, AtT-20 (mouse pituitary
corticotrope), NLT (mouse GnRH-expressing tumor
from the nasal region outside the CNS), NIH 3T3, Y1
(mouse adrenal), aT1–1 (mouse pituitary), aT3–1
(mouse pituitary gonadotrope), CV1 (monkey fibro-
blast), HeLa (human cervical fibroblast), and JEG-3
(human choriocarcinoma). From the panel of nuclear
extracts, it appears that complex 2 is not present in
any of the other cell types tested. In JEG-3 cells, a
complex exists that migrates slightly faster than com-
plex 2 from GT1–7 cells. It is possible that the protein
from JEG-3 cells is a human homolog of the complex
2 protein in mice, but it is more likely that this complex
from JEG-3 cells is a different protein from complex 2.
Complex 1 is present in GT1–7 nuclear extract and
appears to comigrate with complexes seen in NLT,
aT3–1, and aT1–1 nuclear extracts. Thus, complex 1 is
partially cell specific and complex 2 is unique to GT1–7
cells, in the tested cell types.
Q50 Homeodomain Transcription Factor Binding
Sites Found within Footprint 2
To identify the protein(s) contained in complex 2, we
examined the nucleotide sequence for known protein-
binding elements. The 263 to 233 region contains a
CAATTA region (Fig. 6A, middle site) that is homolo-
gous to a C/EBP and a homeodomain-binding site.
Previously, we found that C/EBPb, although present in
GT1–7 cells, does not bind to this site, termed the
middle site by Eraly et al. (11). Homeodomain tran-
scription factors recognize an ATTA DNA core motif.
Those homeodomains with a glutamine at position 50
(Q50) bind a CAATTA or CCATTA motif while a lysine
labeled at left and right were previously identified by their ability to be competed by 100-fold excess of unlabeled oligonucleotide.
B, There are no differences in Oct-1 complex formation between GT1–7, NIH 3T3, and aT3–1 nuclear extracts with the octamer
consensus probe. Competitions were conducted: none (no competitor) or self (100-fold excess unlabeled octamer consensus
site).
Fig. 5. Complex 1 and Complex 2 from GT1–7 Nuclear Ex-
tract Are Relatively Cell-Specific Complexes
An EMSA was conducted using the 263/233 probe and
nuclear extracts from the different cell types, indicated above
each lane. The specific complexes labeled at left and right
were previously identified by their ability to be competed by
100-fold excess of unlabeled oligonucleotide. Arrow at bot-
tom right indicates migration of free probe.
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at position 50 (K50) recognizes a GGATTA motif (18).
By sequence comparison, it appears that both the
middle and downstream sites contain Q50 homeodo-
main binding elements (Fig. 6A). Few of the specific
Q50 homeodomain binding sites have been deter-
mined; the best characterized include engrailed (en),
antennapedia (antp), and fushi tarazu (ftz) (19–21). Ftz
is a member of the antp family of homeodomain pro-
teins while en is a member of a separate family (22). En
and ftz are Q50 homeodomain transcription factors
that bind a core site of CAATTA, an 8 out of 10 match
to the middle site in FP2 (Fig. 6A) (20, 21). The down-
stream site of the 263/233 promoter element is also
homologous to a Q50 homeodomain binding site that
can be bound by ftz or antp, based on the core
CAATTA motif (19). Thus, it is possible that members
of the Q50 homeodomain protein family bind to one or
both of these regions within the 263/233 sequence.
Thus, it is important to determine whether the cell-
specific complexes 1 or 2 are bound to the ATTA
motifs. Previously, we conducted EMSA analysis of
mutations within the 263/233 probe to determine the
regions binding each of the five protein complexes
(11). In Table 1, we show the mutant oligonucleotide
probe sequences below the wild-type 263/233 oligo-
nucleotide probe sequence. The mutant probes lack
the binding of protein complexes to either the middle
site (m2c block mutation) or to the downstream site
(m2e block mutation and m2oct double point muta-
tion) (11). Here we list the previous results in table form
with the addition of a second block mutation in the
middle site, m2d (data not shown), and four mutated
probes corresponding to mutations in the Q50 con-
sensus sites, m2Q1, m2Q2, m2Q3, and m2Q4 (EMSA
shown in Fig. 6B). Complex 5 (Oct-1) and complex 1
are greatly reduced by the m2e and m2oct mutation,
corroborating the binding of the corresponding pro-
teins in the downstream site of FP2 (diagram in Fig.
6C). The new m2d mutation, as well as the previously
documented m2c mutation, eliminates complex 4
binding, suggesting that complex 4 binds to the mid-
dle FP2 binding site. Complex 3 is eliminated by all of
the block mutations including m2d, confirming that
dramatic changes in the 263/233 oligonucleotide dis-
rupt complex 3. We previously indicated that m2c
does not disrupt complex 2 formation (11), but a more
detailed analysis shows a reduction in complex 2 for-
mation on the m2c block mutation oligonucleotide
probe (see also Fig. 7A).
Since the m2c mutation does not completely eliminate
complex 2 formation, it is possible that complex 2 binds
to a site at the downstream end of 263/233. An ATTA
motif is present in both the middle and downstream
sites. To investigate the location of binding of complex 2,
targeted mutations were created in the 263/233 oligo-
nucleotide probe (Table 1 for compiled data and muta-
tion sequences). Mutation of the middle ATTA site to
GGGG (m2Q1) results in decreases in complexes 1, 2, 3,
and 5 while complex 4 is completely eliminated (Fig. 6B).
A smaller mutation in the middle site, changing the first
Fig. 6. Potential Q50 Homeodomain Protein Binding Sites
in Footprint 2
A, The GnRH promoter 263/233 region contains two
possible Q50 homeodomain binding sites. The 263/233
oligonucleotide is shown with boxes encompassing two
regions of homology with the fushi tarazu/engrailed (ftz/en)
consensus site (middle site and downstream site). Bold
sequences correspond to the core Q50 homeodomain
binding site, and underlining identifies regions of homology
to a Q50 binding site. Alignment of the Q50 consensus
binding site probe (Q50) is with the middle binding site
within FP2 of the GnRH promoter (middle site). The Q50
oligonucleotide region within the box indicates the ftz/en
consensus binding site and encompasses the middle site
in the 263/233 element. Vertical lines identify the bases
that are conserved between the Q50 consensus site and
263/233. B, EMSAs were conducted with GT1–7 nuclear
extract and the indicated probes. The specific complexes
labeled at left and right were previously identified by their
ability to be competed by 100-fold excess of unlabeled
oligonucleotide (not shown). Arrow at bottom right indi-
cates migration of free probe. C, 263/233 oligonucleotide
sequence is shown with the likely complex binding sites.
Bars above and below the sequence show the region likely
bound by each complex listed.
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and fourth A’s to G’s (m2Q2), results in a decrease in
complex 2 binding and elimination of complex 4. The
same mutation in the downstream ATTA site (m2Q3)
decreases binding of complexes 1 and 2 and eliminates
binding of complex 5 (Oct-1), as expected (see above).
Since complex 4 is retained by the probe containing the
downstream mutation, it is clear that this complex re-
quires an intact middle ATTA site although it is not a
cell-specific complex (see Fig. 5). Complex 2 appears to
bind to the CAATTA motif in the middle site (255 to 250)
Fig. 7. The 263/233 Region Binds a GT1–7 Cell-Specific Protein Related to the Q50 Homeodomain Family
A, The GT1–7 specific complex bound to the Q50 consensus site comigrates with complex 2 from GT1–7 nuclear extract.
EMSAs were conducted as described in Materials and Methods with 263/233, m2c, and Q50 probes, as indicated. The five
specific complexes bound in GT1–7 nuclear extract to 263/233 are indicated at the left. The Q50-specific band is indicated by
the arrow at left and is absent in the lanes with NIH 3T3 extract (A, right). The arrow at bottom right indicates migration of free
probe. Nuclear extracts from GT1–7 cells (left) and NIH 3T3 cells (right) were used in the EMSA. B, Complex 2 is competed by
the Q50 probe. EMSA was conducted using GT1–7 nuclear extract. Competitions with 100-fold molar excess of the indicated
oligonucleotide were conducted; none (no competitor added), self (same oligonucleotide as the indicated probe), m2c (263/233
with m2c mutation), Q50 (oligonucleotide with ftz/en consensus binding site) and Q50mut (Q50 oligonucleotide with mutation in
homeodomain consensus site).
Table 1. The Binding of Complexes to Mutated Oligonucleotides within the 263/233 Element
DNA-Binding Complex
263 233 1 2 3 4 5
u u
WT AGGTGTTCCAATTACATTCCTCATTAAATGG 111 111 111 111 111
m2c AGGTGGCGGCCGCACATTCCTCATTAAATGG 111 1 2 2 11
m2d AGGTGTTCCAGCGGCCGCCCTCATTAAATGG 1 111 2 2 11
m2e AGGTGTTCCAATTACATTGCGGCCGCAATGG 2 111 2 111 2
m2oct AGGTGTTCCAATTACATGCCTCAGTAAATGG 2 11 11 11 2
m2Q1 AGGTGTTCCAGGGGCATTCCTCATTAAATGG 1 1 1 2 1
m2Q2 AGGTGTTCCAGTTGCATTCCTCATTAAATGG 11 1 1 2 2
m2Q3 AGGTGTTCCAATTACATTCCTCGTTGAATGG 1 1 1 111 2
m2Q4 AGGTGTTCCAGTTGCATTCCTCGTTGAATGG 1 2 2 2 2
Wild-type and mutant oligonucleotide probes are depicted as used for the EMSA in Fig. 6B and in previous publications (11). At
right, the band intensity of each complex is indicated (111 is maximum, 1 is minimum, and 2 is no band present) from Fig. 6B
and Eraly et al. (11), with the numbers 1 to 5 indicating the five protein complexes.
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and an ATTA motif (241 to 238) present in the down-
stream site. Conversely, complex 2 may also be main-
tained by protein-protein interactions even when its DNA
recognition sequence has been disrupted. Complex 1 is
relatively cell specific (see Fig. 5) and binds the identical
site as Oct-1, as is shown by its retention on the probe
with the point mutations of the middle site and its reduc-
tion by mutations in the downstream site. Finally, an
oligonucleotide probe containing the point mutations in
both middle and downstream sites (m2Q4) reduces
binding of complex 1 and eliminates binding of the re-
maining complexes (Fig. 6B). A diagram summarizing the
proteins binding to 263/233 is shown in Fig. 6C.
263/233 Binds a Complex That Comigrates with
a Complex Binding to a Q50 Homeodomain
Consensus Site
To determine whether proteins expressed in GT1–7
cells can bind a consensus Q50 binding site (repre-
sented by the binding site for en and ftz, termed Q50),
EMSA was conducted with 263/233, m2c, and Q50
as probes (Fig. 7A). In GT1–7 nuclear extract, the Q50
probe is bound by a protein complex that comigrates
with complex 2 on the probe 263/233. This complex
is not present in NIH 3T3 cell nuclear extract (Fig. 7A,
arrow) or other cell types (see Fig. 5). In EMSA with
nuclear extracts from hypothalamus and forebrain, but
not cerebellum, a complex is observed to comigrate
with complex 2 using the Q50 probe (data not shown).
Furthermore, the Q50 oligonucleotide competes for
the binding of complex 2 bound to the 263/233 probe
while a mutated Q50 oligonucleotide (Q50mut) does
not compete for the complex (Fig. 7B). Additionally,
263/233 competes for binding of the specific com-
plex bound to Q50 (arrow) while the m2c oligonucle-
otide (disruption of the middle site) does not compete
(Fig. 7B). The two slower mobility complexes, which
are abundant in both GT1–7 and NIH 3T3 nuclear
extract, are not competed for by the 263/233 oligo-
nucleotide. These data suggest that a Q50 homeodo-
main transcription member binds to 263/233 specif-
ically in GT1–7 nuclear extract, perhaps modulating
the cell-specific interactions between the GnRH en-
hancer and promoter.
DISCUSSION
Specification of the expression of individual genes
during the complex processes of development and
cellular differentiation is one of the most challenging
problems in the field. This central question becomes
all the more compelling when the tissue involved is the
brain and the target is a unique, well defined set of
neurons. Little is known about the neuronal regulatory
elements and transcription factors that restrict the ex-
pression of individual genes to exclusive populations
of neurons. The study of expression of the GnRH gene
in the GT1–7 cell line provides an opportunity to elu-
cidate the molecular mechanisms for neuron-specific
gene expression.
In the simplest cases, cell type-specific gene ex-
pression can be traced to the presence of transcription
factors unique to the individual cell types (23–25). As
more is known about tissue-specific control regions, it
has been discovered that they often comprise com-
plexes of interacting elements and regulatory proteins
with or without uniquely tissue-specific factors (26–
28). These more complex control regions may have
evolved to integrate diverse spatial and temporal in-
formation in determining cell fate. The GnRH gene
thus far falls into the latter class in that the proteins
identified to date are expressed in many cell types.
The GnRH regulatory region comprises an enhancer
and a proximal promoter, which combined, can confer
uniquely targeted expression in transgenic animals,
but the enhancer on a heterologous (RSV) promoter is
inadequate (M. A. Lawson and P. L. Mellon, unpub-
lished results). Thus, the enhancer must act coordi-
nately with the elements in the promoter. This high
degree of interdependence between the regulatory el-
ements may be a quality adapted for specifying ex-
pression to a very rare cell type, since activation re-
quires the simultaneous presence of multiple specific
proteins, some of which bind to both the enhancer and
the promoter (11, 16).
The synergistic activation of transcription by the
combination of the GnRH enhancer and promoter reg-
ulatory regions is specific to GT1–7 cells and GnRH
neurons. Thus, the GT1–7 cells express the proteins
necessary to facilitate the interaction between the en-
hancer and promoter, whereas other cell lines, such as
NIH 3T3 cells, do not. Using transient transfections,
we previously found that the GnRH enhancer can con-
fer cell-type specificity without the GnRH proximal
promoter (5). In this study, we have demonstrated that
the promoter can also confer a degree of cell type
specificity in the absence of the GnRH enhancer. FP2
strongly contributes to cell type specificity, since de-
letion of FP2, when the GnRH promoter is coupled
with the RSV enhancer, abolishes preferential reporter
gene expression in GT1–7 cells (Fig. 2B). The speci-
ficity of FP2 action is further demonstrated by fusion to
the GnRH enhancer or the RSV enhancer, upstream of
the RSV promoter. In these instances, FP2 increased
the activity ratio by only 2-fold in NIH 3T3 cells but by
15-fold in GT1–7 cells (Fig. 3, A and B). Finally, we
have identified a subregion of FP2, 263/233, that
specifically interacts with the GnRH enhancer in
GT1–7 cells.
The footprint 2 region of the GnRH gene proximal
promoter is complex (reviewed in Ref. 16). It was
shown previously that deletion of the FP2 element
results in a 20-fold loss of transcriptional activation,
the most dramatic loss in activation of any of the
promoter deletions (6). Although data from DNase I
footprint analysis of block mutations in the promoter
suggests the binding of three protein complexes,
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EMSA reveals five individual complexes within the
middle and downstream site (11). This region also
confers responsiveness to both phorbol esters and
glucocorticoids. Previous data also show the induc-
tion of a slower mobility complex by the phorbol ester
TPA, a protein kinase C activator (6). Furthermore, the
glucocorticoid receptor binds to the 59-region of FP2
in the equivalent area in the mouse GnRH promoter
(29). Thus, the GnRH proximal promoter element, FP2,
confers neuronal specificity to GnRH gene expression,
as well as responsiveness to hormones and second
messengers.
Although FP2 is necessary for conferring several
responses to GnRH gene expression, little is known
about the proteins that bind to this region. Previously,
we had identified Oct-1 binding to the 39-portion of
FP2 (11). Oct-1 may play a role in cell-specific activa-
tion of GnRH expression through unique interactions
with other ubiquitous transcription factors, through
interactions with a GnRH neuron-specific activator, or
through interactions coupling the GnRH enhancer to
the GnRH promoter. The data presented here show
that FP2 of the GnRH promoter can greatly augment
transcriptional activation by the GnRH enhancer,
thereby demonstrating cross-talk between FP2 and
the GnRH enhancer. Oct-1 may be one of the regula-
tors required for this interaction, particularly in consid-
eration of its critical role in transcriptional activation
through binding sites in the enhancer (7).
To identify potential cell-specific proteins in GT1–7
cells, we compared EMSA between GT1–7 and vari-
ous other cell types. Three differences exist between
GT1–7 and NIH 3T3 nuclear factors binding to the
263/233 region of the promoter that could play a role
in cell-specific expression of GnRH. First, Oct-1 con-
taining complexes are not detected by EMSA that
include the 263/233 region of the GnRH promoter
and nuclear extract from NIH 3T3 cells, in contrast to
assays containing nuclear extract from GT1–7 cells.
Rather, in assays utilizing nuclear proteins derived
from NIH 3T3 cells, a strong, comigrating, but as yet
unidentified, complex forms. It is possible that this
complex masks Oct-1 binding or that the formation of
the strong, low-mobility complex occludes Oct-1
binding by occupying nucleotide sequences neces-
sary for Oct-1 interaction with the 263/233 site. As
mentioned earlier, binding sites for Oct-1 are also
present in the GnRH enhancer, and it is possible that
the synergy between the two elements could be due to
Oct-1 or an Oct-1 binding partner. Although formation
of Oct-1 complexes on the 263/233 site with NIH 3T3
nuclear extract is not observed, Oct-1 complexes from
pituitary-derived aT3–1 nuclear extracts are detected.
Furthermore, expression through the GnRH enhancer
and promoter in aT3–1 cells is lower than in NIH 3T3
cells (data not shown), indicating that the ability of
Oct-1 to bind 263/233 alone is not sufficient to confer
cell-specific expression. This observation suggests
that other factors dependent on Oct-1 interaction may
be important for cell-specific activation of the GnRH
promoter rather than Oct-1 itself.
A second candidate for cell-specific activation is
complex 1. This complex is not present in NIH 3T3
nuclear extract whereas it appears to be present in
aT3–1 nuclear extract by EMSA comigration experi-
ments. Again, since aT3–1 cells express lower levels
of reporter gene driven by the GnRH enhancer and
promoter than NIH 3T3 cells, the presence of complex
1 is not sufficient to facilitate cell-specific interactions
between the GnRH promoter and enhancer. A third
candidate, that which forms complex 2, is relatively
unique to GT1–7 cells by EMSA and may account for
the differences seen in transcriptional regulation be-
tween the cell types. As described earlier, the GnRH
enhancer fused to the 43263/233 region results in a
higher reporter expression in GT1–7 cells compared
with NIH 3T3 cells. To further support this idea, the
m2c mutation in the 263/233 EMSA probe decreased
binding of complex 2 (Fig. 7A). When the m2c mutation
is present in the context of the whole promoter and
enhancer, reporter gene expression is only 25% of
wild type, the most significant decrease of all of the
FP2 mutations examined to date (11). Thus, it is likely
that complex 2 plays a role in maintaining cell type
specificity and in transcriptional activation of GnRH
expression.
Complex 2 is our best candidate for a cell-specific
protein binding to FP2. Expression of complex 2 ap-
pears to be restricted to GT1–7 cells and to bind a
potential Q50 homeodomain transcription factor site,
CAATTA. This site is also present in repeating ele-
ments in the 39-region of the GnRH enhancer. EMSA
experiments have confirmed that complexes that form
on these elements in GT1–7 nuclear extracts comi-
grate with complex 2 (data not shown, C. G. Kelley and
P. L. Mellon, personal communication). This similarity
suggests that complex 2 may also bind to the GnRH
enhancer and could subsequently foster interactions
between the two regulatory regions.
All homeodomain transcription factors bind to the
core motif ATTA, which makes it difficult to identify the
protein binding by simple binding site homology. Ad-
ditionally, only a few specific homeodomain DNA-
binding sites have been well characterized. To date,
antennapedia, engrailed, and fushi tarazu are the only
homeodomain proteins known to bind to a CAATTA
site (21), and the crystal structure of engrailed bound
to TAATTA has been shown (30). In EMSA experiments
we have identified a complex that binds specifically
with GT1–7 nuclear extract to both the 263/233
probe and the CAATTA site. We have not yet identified
the protein(s) in this complex since supershift antibod-
ies are not available for Q50 homeodomain candi-
dates, antennapedia, engrailed, or fushi tarazu. We
have found engrailed 2 RNA and protein in GT1–7
neurons (data not shown) but engrailed 2 has not been
shown to be expressed in regions known to contain
GnRH neurons (31, 32). Furthermore, Hox proteins,
mammalian homologs of antennapedia, are not ex-
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pressed in the forebrain, and fushi tarazu has no
known mammalian homolog. Thus, complex 2 binds
to a core homeodomain site in the GnRH promoter and
may be a novel or previously identified member of the
Q50 homeodomain family. Future experiments will fo-
cus on identification of this cell-specific regulator of
GnRH gene expression.
In conclusion, we have identified a 31-bp region
(263 to 233) of the rat GnRH promoter that interacts
with the GnRH enhancer to increase cell-specific tran-
scription. This region binds Oct-1, which may interact
with other ubiquitous or specific transcription factors
to control the cell-specific expression. Binding of
Oct-1 to the GnRH enhancer and to FP2 of the pro-
moter also may be crucial for the interaction between
these two DNA regulatory elements. The data pre-
sented here substantiate the assertion that the inter-
actions occurring between the GnRH enhancer and
GnRH promoter are necessary for cell-specific re-
porter gene expression. We have identified cell-
specific complexes binding the GnRH promoter that
may play a role in interactions between the GnRH
enhancer and promoter to control cell-specific expres-
sion of GnRH. Here, we suggest that a Q50 homeodo-
main transcription factor binds to a region of the GnRH
promoter that is crucial for neuron-specific interac-
tions with the GnRH enhancer. This protein may inter-
act with other proteins, such as Oct-1 bound to the
GnRH promoter and/or enhancer to confer cell-
specific expression. Further investigations of cognate
binding proteins and their protein-protein interactions
will help to clarify the role of the FP2 element in GnRH
transcription, elucidating the molecular mechanisms
underlying the interactions between the enhancer and
promoter of the GnRH gene.
MATERIALS AND METHODS
Plasmids and Cloning
The rGnRHe/rGnRHp-luc plasmid contains the rat GnRH en-
hancer (21571 to 21863; in reverse orientation) and rat
GnRH promoter (2173 to 1112) in the pGL3 basic vector,
controlling luciferase gene expression. Deletions of the rat
GnRH promoter were created as previously described (11).
Briefly, deletion of FP6 and FP7 retains 2126 to 1112; de-
letion of FP2 retains 2173 to 270 and 228 to 1112; deletion
of FP3, 4, 5, 6, and 7 retains 282 to 1112; and deletion of
FP2, 3, 4, 5, 6, and 7 retains 228 to 1112. In addition, the
plasmid with the internal deletion of FP3, 4, and 5 retains the
2173 to 2128 and 274 to 1112 region. These regions were
subcloned from the CAT vectors into the pGL3 vector (Pro-
mega Corp., Madison, WI), containing the rat GnRH en-
hancer. The RSVe/rGnRHp-luc plasmid was created by plac-
ing the enhancer region of the RSV 59-LTR and the rat GnRH
promoter (2173 to 1112) upstream of the luciferase gene in
pGL3 basic. To place the RSV enhancer adjacent to the
promoter deletions, the promoter deletions were transferred
from the pGL3 vector containing the rGnRH enhancer to the
pGL3 vector containing the RSV enhancer. The rGnRHe/
RSVp-luc plasmid contains the rat GnRH enhancer (21571 to
21863) and the promoter region from the RSV 59-LTR in the
pGL3 basic vector. RSVe/RSVp-luc contains the enhancer
and promoter regions of the RSV 59-LTR in the pGL3 basic
vector. RSVe/RSVp-gal was created by removing the lucif-
erase gene from the RSVe/RSVp-luc plasmid and replacing it
with b-galactosidase from pSV-b-galactosidase (Promega
Corp.).
To create rGnRHe/FP2/RSVp-luc, the FP2 region (282 to
221) was inserted between the rat GnRH enhancer and RSV
promoter in the rGnRHe/RSVp-luc vector. RSVe/FP2/RSVp-
luc contains RSVe/RSVp-luc with FP2 (282 to 221) inserted
in the polylinker between the RSV enhancer and RSV pro-
moter. The 263/233 region was multimerized by using a
synthesized oligonucleotide with the following sequence: 59-
CTAGAAGGTGTTCCAATTACATTCCTCATTAAATGG3-9 and
59- CTAGTCCATTTAATGAGGAATGTAATTGGAACACCTT - 39.
The oligonucleotide was annealed and inserted into pBSK1. To
create the four multimer site, multiple rounds of digestion and
ligation were conducted. The 43 263/233 multimer was then
inserted between the enhancer and promoter of rGnRHe/RSVp-
luc and RSVe/RSVp-luc to create rGnRHe/4363/RSVp-luc and
RSVe/4363/RSVp-luc, respectively.
Cell Culture and Transfections
GT1–7 and NIH 3T3 cells were cultured in DMEM containing
10% FCS (Omega Scientific, Tarzana, CA), Penn/Strep, glu-
cose, and sodium bicarbonate. These cells were incubated in
5% CO2 at 37 C. For transient transfections, GT1–7 cells
were split 1:3 and NIH 3T3 were split 1:25 from 100% con-
fluent plates in 6-cm plates. Cells were incubated overnight
and were transfected with calcium phosphate (33). Briefly,
7.2 mg of reporter DNA and 2.2 mg of internal control DNA
were added to a 15-ml conical tube; 23 HBS (0.5 ml) was
added to the DNA and briefly vortexed, and 0.25 M calcium
chloride (0.5) was added drop wise into the tube while vor-
texing at low speed. The precipitate was incubated 5 min at
room temperature before addition of 0.5 ml to one 6-cm plate
of GT1–7 cells and one 6-cm plate of NIH 3T3 cells. Sixteen
hours later the cells were washed two times with PBS, and
DMEM 10% FCS was replaced. Cells were incubated 24 h
longer and harvested.
Harvesting cells entailed washing the cells three times with
PBS and adding harvesting buffer (0.5 ml; 0.15 M NaCl, 1 mM
EDTA, and 40 mM Tris-HCl, pH 7.4). Cells were scraped from
the plate and placed in 1.5-ml tubes and spun for 30 sec at
14,000 rpm. Buffer was removed, lysis buffer (50 ml; 100 mM
potassium phosphate, pH 7.8, 0.2% Triton X-100) was
added, and cells were resuspended by vortexing. Cells were
spun for 5 min, and supernatant was placed into a new tube
and assayed for luciferase and b-galactosidase activity (Ga-
lacto-Light Plus Kit, Tropix, Inc., Bedford, MA). For the lucif-
erase assay, cell lysate (10 ml) was assayed in a 96-well plate,
which was read in a luminometer (Microlumat Plus; Micro-
plate Luminometer LB96V; EG&G Berthold, Gaithersburg,
MD) using luciferin assay buffer (100 ml; 100 mM Tris, pH 7.8,
15 mM MgSO4, 10 mM ATP and 65 mM luciferin). For the
b-galactosidase assay, cell lysate (10 ml) and 0.25 M Tris, pH
7.8 (10 m l), were combined and incubated at 48 C for 50 min.
This was transferred to a 96-well plate, and diluted Galacton-
Plus Substrate (70 ml; 1:100 in Galacto-Light Reaction Buffer
Diluent) was added to each well. The plate was incubated for
15 min and assayed using the luminometer. Light Emission
Accelerator (100 ml) was injected into each well and read for
10 sec after a 2-sec delay. The luciferase and b-galactosi-
dase values for a nontransfected plate of cells were sub-
tracted from each transfected plate value. Then luciferase
values were divided by the b-galactosidase values to control
for transfection efficiency.
Normalizing Transfection Data and Statistics
To control for differences in expression between the different
cell types, each experiment was normalized. The RSV en-
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hancer fused to the RSV promoter driving luciferase (RSVe/
RSVp-luc) was transfected in duplicate in each experiment.
The internal control, RSVe/RSVp fused to b-galactosidase
(RSVe/RSVp-gal), was used as an internal control for each
transfected plate of cells. The RSVe/RSVp-luc luciferase val-
ues were divided by the RSVe/RSVp-gal b-galactosidase
values and averaged. The average was set to 1, and the
values for the other plates were normalized to this value in the
individual cell types. Thus, the values from the individual cell
types can be directly compared. The mean of at least three
experiments is depicted. The error bars represent SEM. In Fig.
1, a single-factor ANOVA and Dunnett’s Least Significant
Difference (LSD) Test were used to determine significant
difference. In Figs. 2 and 3, significance was measured by
paired t test analysis, P # 0.05 as indicated by asterisks.
Oligonucleotides
The 263/233 oligonucleotide corresponds to the sequences
263 to 238 and 259 to 233. The m2c, m2d, and m2e oligo-
nucleotides are identical to the 263/233 oligonucleotide except
for the substitution of 59-GCGGCCGC-39 at 258 to 251, 253 to
246, and 245 to 238, respectively. The m2oct oligonucleotide
is identical to 263/233 with a substitution of a G for the T at
positions 247 and 240. The m2Q oligonucleotides are identical
to 263/233 with the substitution of G’s for the ATTA from 250
to 253 (m2Q1), a G for the A at positions 250 and 253 (m2Q2),
a G for the A at positions 238 and 241 (m2Q3), and a G for the
A at positions 238, 241, 250, and 253 (m2Q4). The fushi
tarazu/engrailed (ftz/en) consensus binding oligonucleotide
(Q50) corresponds to the sequences CTAGGAAATGTCAATTA-
AATATCAAG (top strand), and GATCGCTTGATATTTAATTGA-
CATTC (bottom strand). The ftz/en consensus mutant (Q50mut)
oligonucleotide corresponds to the sequences CTAGGAAAT-
GTCAGGGAATATCAAG (top strand) and GATCGCTTGATAT-
TCCCCTGACATTTC (bottom strand). Oligonucleotides were
synthesized by Operon Technologies (Alameda, CA) and were
annealed in 50 mM NaCl by heating to 95 C for 5 min and slowly
cooling to room temperature.
EMSA
Nuclear extracts were prepared according to the method de-
scribed by Schreiber et al. (34). Annealed wild-type and mutant
oligonucleotides (1 pmol) containing sequences of the GnRH
promoter and consensus sequences were filled in with
a[32P]dATP (3000 Ci/mmol Dupont NEN Life Science Products,
Boston, MA) and Klenow using standard procedures (35).
Probes were phenol/chloroform extracted and passed over
G-50 micro columns (Amersham Pharmacia Biotech, Piscat-
away NJ). Probes were counted in a scintillation counter and
diluted in 50 mM NaCl. The competitor oligonucleotide was
end-filled with Klenow. Binding reactions were carried out in 10
mM HEPES-KOH, pH 7.8, 50 mM KCl, 1 mM EDTA, 5 mM
spermidine, 5 mM DTT, 0.2 mg/ml BSA, 0.5 mM phenylmethyl-
sulfonylfluoride, 12.5–25 mg/ml polydeoxyinosinic-deoxycyti-
dylic acid, 10% (vol/vol) glycerol, and 20 mg/ml Ficoll. One
femtomole of each probe was incubated with 2 mg of GT1–7
crude nuclear extract in 20 ml reactions. Reactions were incu-
bated at room temperature for 5 min, loaded, with current on,
into a 5% polyacrylamide gel [30:1 acrylamide/bisacrylamide,
0.25 3 TBE (130 mM Tris, 45 mM boric acid, 2.5 mM EDTA), 5%
glycerol], and electrophoresed for 2 to 3 h at 175 V. Gels were
prerun for 30 min in 0.25 3 TBE. After electrophoresis, gels were
dried and subjected to autoradiography. Competition reactions
were performed by preincubating the reactions with the speci-
fied amount of excess unlabeled oligonucleotide for 20 min
before the addition of probe.
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